Generic placeholder image

Current Pediatric Reviews


ISSN (Print): 1573-3963
ISSN (Online): 1875-6336

Review Article

Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Novel Therapy for Multidrug Resistant Gram Negative Infections in Children

Author(s): Brittany A. Rodriguez, Jennifer E. Girotto and David P. Nicolau*

Volume 14 , Issue 2 , 2018

Page: [97 - 109] Pages: 13

DOI: 10.2174/1573396314666180308150908

Price: $65


The rise in Multidrug-resistant (MDR) infections has become a significant problem in both the developing countries and in the United States (U.S.). Specifically, MDR gram-negative infections are emerging, affecting not only adults but children as well. The specific gram-negative organisms that have been most concerning within the pediatric population include MDR P. aeruginosa, Enterobacteriaceae, and Acinetobacter spp.

The increase in antimicrobial resistance rates is associated with various mechanisms with one of the most common being the production of beta-lactamases. Both Ceftazidime/Avibactam (CZA) and Ceftolozane/Tazobactam (C/T) are two recently approved antibiotics in the U.S. While both of these agents are inhibitors of beta-lactamase enzymes, there are differences between them that are important to understand. At this time, the data in children for these agents are extremely limited. The aim of this review is to describe the characteristics of these agents and their potential uses in pediatric patients.

Keywords: beta-lactam/beta-lactamase inhibitor, ceftazidime/avibactam, ceftolozane/tazobactam, children, Enterobacteriaceae, multidrug resistance.

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy